GeneDx Third Quarter 2026 Earnings Conference Call - GENEDX HOLDINGS CORP

Financial Performance:

• Total Q3 2026 revenue was $123.1 million, driven by $110.4 million in exome and genome revenue, representing a $10 million sequential increase.
• Adjusted gross margin expanded to 72% (up from 70% in Q2 and 69% in Q1).
• Adjusted net income reached $8.6 million, a significant improvement from an $8.2 million loss in Q1 and near-break-even in Q2.
• Reported 32,100 exome and genome tests; underlying order accessions grew 28% sequentially, indicating strong demand outpacing current throughput.
• Blended average reimbursement rate increased 5% sequentially to $3,436 (up from $3,258 in Q2); Q4 guidance targets ~$3,500 per test.
• Genome cost per test (COGS) decreased 43% year-over-year, with further reductions expected to narrow the gap with exome COGS.
• Full-year revenue guidance remains $475–$490 million; gross margin guidance raised to ~71%; adjusted net income guidance raised to at least $12 million.
• 2026 volume guidance adjusted to 28% growth, implying ~17% revenue growth.

Guidance and Future Outlook:

• Q4 2026 outlook: Revenue ~$135 million (exome/genome ~$121 million), adjusted gross margin ≥71%, adjusted net income ~$12 million, and volume of 34,500 tests.
• Full-year 2026 volume expected to grow 28%; Q1 2027 projected to follow typical seasonal weakness, with Q4 seasonality expected to be stronger than Q3.
• Fiscal 2027 specific guidance was not provided, but management expects a positive trajectory entering 2027 with revenue growth rates converging with volume growth as RCM improvements mature.
• 2027 revenue is expected to face a mid-single-digit headwind from PAMA (PAMA) affecting ~45% of revenue, which management believes will be offset by RCM tailwinds and COGS reductions.
• Long-term goal to make genome sequencing the standard for diagnosing heritable disease; expects genome mix to rise again in 2027 as collection rates improve and COGS decline.
• Expect to continue adding commercial sales hits in 2027 based on ROI, though not at the scale of 2026's initial market expansion.

Business Segments and Product Lines:

• Exome and genome remain the core; genome mix currently at 26% of outpatient volume (down from 32% in Q2) due to strategic mix management favoring higher-margin exome in the near term.
• New ordering features, simplified reports, and post-test guides launched to drive adoption across care settings.
• Long-range sequencing added to the genome portfolio; early access program initiated with key opinion leaders.
• "GenPeds" (general pediatricians) segment identified as the largest single segment for volume growth in 2027; team entered field in February and is already profitable.
• GDX Infinity biopharma and data business grew for the second consecutive quarter, adding Mirum Pharmaceuticals and Barron Therapeutics as sponsored partners.
• Medicaid exome coverage expanded to 37 states; genome coverage in 25 states (up from 23). Carillon policy expansion covering ~56 million lives showing early positive collection signals.

Market and Competitive Landscape:

• GDX maintains market leadership in core segments (geneticists, pediatric neurologists) with strong growth in productivity per clinician.
• Demand remains strong across all markets; management views competition as a catalyst for changing the "status quo" of low testing utilization.
• NICU and prenatal markets are growing faster than the overall company; NICU growth is limited by programmatic execution disparities, while prenatal growth awaits guideline updates.
• Market access strategy includes a new Chief Patient Access Officer (Nicole Masson) to advance payer partnerships and government relations.
• 98% of commercial lives have positive exome coverage policies; 88% have positive genome coverage policies.

Risks and Challenges:

• Revenue Cycle Management (RCM) transformation creates near-term volume friction; up-front documentation requirements have delayed test initiation (accessions +28% vs. volume +25%).
• 62% of test denials are administrative/procedural (addressable); 38% are due to clinical necessity disputes or lack of coverage (longer-term fix).
• PAMA legislation exposure: ~45% of revenue tied to fee schedules could face mid-single-digit revenue headwinds in 2027.
• Slow operationalization of payer policy changes by insurers may delay the full realization of collection rate improvements.
• Genome COGS remains significantly higher than exome, though the gap is narrowing rapidly.

Management Commentary and Tone:

• Tone is confident and forward-looking, emphasizing "profitable execution" and a deliberate shift from "volume at all costs" to "paid volume."
• Management expressed strong confidence in demand strength and the market opportunity, viewing current volume dips as temporary friction from necessary RCM process improvements.
• Leadership highlighted the successful hiring of new RCM, market access, and finance executives who validated the multi-year transformation plan.
• Emphasis on the "GDX Infinity" data asset as a compounding competitive advantage for interpreting rare variants and enabling biopharma partnerships.

Analyst Questions and Answers:

• Volume vs. Documentation: Confirmed that the 3% delta between accessions and volume is primarily a timing delay (few days) due to new documentation requirements, not lost demand; expect this to compress over time.
• GenPeds Growth: Clarified that GenPeds will be the largest single segment growth driver in 2027, not necessarily larger than all other segments combined, but high contribution margin.
• RCM Timelines: Collection rate improvements (e.g., genome collections up 400 bps to 36%) are occurring now; full AI-driven RCM architecture implementation expected to drive more significant results in 2027.
• Competitive Landscape: No observable shift in competitive behavior; management believes competition helps expand the total addressable market by challenging the status quo of delayed diagnoses.
• Medicaid vs. Commercial: In states with mature Medicaid coverage, collection rates exceed commercial rates; overall Medicaid collections are depressed by states lacking enacted coverage policies.
• Exome COGS: Exome COGS is near optimized and relatively flat; genome COGS has improved 43% YoY with further reductions anticipated.

Other Key Points:

• Nicole Masson joined as Chief Patient Access Officer to leverage experience from Exact Sciences in transforming market access strategy.
• 92% of volume is outpatient insurance-based; Medicaid is the largest payer segment at 48%.
• Trio testing (parents as comparators) volumes have reverted to historic norms after a spike in new market launches.
• GDX Infinity data enables matching of de novo variants across patients, a unique capability for confirming rare genetic diagnoses.
• Management plans to continue integrating with Epic Aura and other EHR systems to automate documentation collection and improve user experience.